Randomized controlled trials and real life studies: Approaches and methodologies: a clinical point of view.

S. Saturni a, F. Bellini a, F. Braid o b, P. Paggiaro c, A. Sanduzzi d, N. Scichilone e, P.A. Santus f, L. Morandi a, A. Papi a, *

a Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
b Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCS AOU San Martino-IST, Genoa, Italy
c Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Italy
d Section of Respiratory Diseases, Department of Surgery and Clinical Medicine, University of Naples, Italy
e Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Italy
f Dipartimento di Scienze della Salute, Pneumologia Riabilitativa, Fondazione Salvatore Maugeri, Istituto Scientifico di Milano IRCCS, University of Milan, Milan, Italy

A R T I C L E   I N F O
Article history:
Received 3 November 2013
Received in revised form
11 January 2014
Accepted 13 January 2014

Keywords:
Randomized controlled trials
Real life studies
Asthma
COPD

A B S T R A C T
Randomized Controlled Trials (RCTs) are the “gold standard” for evaluating treatment outcomes providing information on treatments “efficacy”. They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the “effectiveness” of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real life trials have high generalizability, but low internal validity. Recently the number of real life studies has been rapidly growing in different areas of respiratory medicine, particularly in asthma and COPD. The role of such studies is becoming a hot topic in respiratory medicine, attracting research interest and debate.

In the first part of this review we discuss some of the advantages and disadvantages of different types of RCTs and analyze the strengths and weaknesses of real life trials, considering the recent examples of some studies conducted in COPD. We then discuss methodological approaches and options to overcome some of the limitations of real life studies.

Comparing the conclusions of effectiveness and efficacy trials can provide important pieces of information. Indeed, these approaches can result complementary, and they can guide the interpretation of each other results.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

Research evolves by answering new questions, including questions on how research itself should be conducted. Randomized Controlled Trials (RCTs) are well recognized as the “gold standard” for evaluating treatment outcomes [1,2]. They are designed to test a therapeutic hypothesis under optimal conditions in the absence of confounding factors: highly selected patients, optimal management conditions, and ideal settings; thus they provide information on “efficacy” under conditions very different from real life [3,4]. They accomplish this through an experimental design [2,5,6] that, as their name implies, always includes randomization to guarantee that treatment groups are as similar as possible in all attributes that could potentially influence outcomes [2,5]. Thus, RCTs have high internal validity under the ideal conditions in which they are conducted [1,2]. Concerns about the conclusions of RCTs relate mainly to their generalizability to broader patient populations and to less ideal conditions, like routine clinical practice, where even health care costs and availability can be problematic [2]. Indeed, it is argued that, because of statistical need of limiting confounding factors, the highly selected population of RCTs only partially
represents the real-life population, casting doubts on the external validity of these clinical trials. Assessment of outcomes under these sub-optimal conditions in observational or pragmatic studies informs on the “effectiveness” of a treatment in real life [3,4], that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances.

Observational studies have the power and structure to identify areas in which investigation is needed and to test new hypotheses [7]. Pragmatic trials are designed to evaluate treatment outcomes, but unlike RCTs they adopt usual care settings and procedures in non-selected patients [7], thus mimicking everyday clinical practice, which provides high external validity. Real life studies have limitations, primarily stemming from the lack of randomization and the need to apply the indications only within the local geographic context.

In the first part of this review, we will mainly refer to real life studies conducted in asthma, where they have a long history, as documented by the large number published in the last 10 years. Recently the number of real life studies in pharmacological has been rapidly growing in other areas of respiratory medicine, particularly chronic obstructive pulmonary disease (COPD). During the same period the overall number of RCTs in asthma and COPD was several times higher and tended to be constant over time: there were on average more than 400 RCTs every year on asthma (±5%) and more than 200 RCTs/year on COPD (±8%).

The progressive increase of real life studies published in the last years and their recognized scientific value [8,9] underline that their role is becoming constructive in respiratory medicine, attracting research interest and debate [10,11]. The second part of the review will consider some of the advantages and disadvantages, strengths and weaknesses of different types of trials and comment on the complementarity between RCTs and real life studies.

2. Randomised Controlled Trials

2.1. RCTs: definition and features

RCTs are research studies that aim to evaluate treatment efficacy [12].

Evidence-based clinical trials start from the formulation of a research hypothesis [13], which may be an evaluation of “superiority” or “equivalence” [13]. The appropriate primary outcome and corresponding measuring tool are chosen [13] and the number of patients is estimated based on statistical parameters, historical data on the working hypotheses, clinically relevant differences and the inherent variability of the primary outcomes.

Random assignment to treatment groups and double blind monitoring minimize bias [13].

The effect of the tested treatment is assessed by comparing it to a control condition, standard treatment or placebo [13]. Different treatment strategies or dosages can also be compared. These criteria maximize internal validity but at the same time, limit generalizability and reduce external validity [14].

2.2. RCTs: advantages

Because of their internal strength, RCTs are universally accepted as the “gold standard” for assessing the effects of therapeutic interventions and of medical devices/equipment under specific controlled conditions [7,15–19].

Historically, the first RCTs available in the respiratory literature addressed community acquired pneumonia (CAP), but they did not follow all of the strict RCT rules. A critical assessment of the early studies revealed design flaws: the diagnosis of pneumonia was not defined in 42.8% of the RCTs, only 33% of the studies were restricted to CAP, and outcomes were not defined in 28.5% of the studies [20]. Moreover, only 38% of the RCTs were double-blinded, and intention to treat analysis was not applied [20]. During the ensuing years, significant improvements were made in all methodological aspects of RCTs in respiratory medicine. One of the most recent published RCT on respiratory infections [21] evaluated macrolide maintenance treatment with azithromycin in adults with bronchiectasis not due to cystic fibrosis (CF) [21]. This study meets the criteria for a well-conducted RCT. It has an appropriate design, randomization, double blinding, placebo control and analysis by intention-to-treat (ITT) [21].

The validity of RCTs is built around precise requisites (Table 1), starting from a careful and rigorous experimental plan. Scientists must establish the aim, the primary and secondary outcomes, size

![Fig. 1. Real life studies in asthma and/or COPD in the last decade. PubMed search: Percent variations in the last decade of published studies on asthma and/or COPD containing the term “real-life” in the title or abstract.](image)

<p>| Table 1 | Advantages and disadvantages of RCTs and real life studies. |</p>
<table>
<thead>
<tr>
<th>RCTs</th>
<th>Real life studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advantages</td>
<td>Non-selected population</td>
</tr>
<tr>
<td></td>
<td>Refer to the usual inhaler techniques</td>
</tr>
<tr>
<td></td>
<td>Randomization</td>
</tr>
<tr>
<td></td>
<td>Realistic therapy adherence</td>
</tr>
<tr>
<td></td>
<td>Rigorous analysis methods</td>
</tr>
<tr>
<td></td>
<td>Logistical and ethical feasibility</td>
</tr>
<tr>
<td></td>
<td>Able to evaluate complex therapies</td>
</tr>
<tr>
<td></td>
<td>Useful to detect rare or late side effects</td>
</tr>
<tr>
<td></td>
<td>Routine practice setting</td>
</tr>
<tr>
<td></td>
<td>Long duration</td>
</tr>
<tr>
<td></td>
<td>Lack of patient selection brings confounding factors</td>
</tr>
<tr>
<td></td>
<td>Lack of randomization</td>
</tr>
<tr>
<td></td>
<td>Absence of blinding</td>
</tr>
<tr>
<td></td>
<td>Residual monitoring bias</td>
</tr>
<tr>
<td></td>
<td>Confounding by indication</td>
</tr>
<tr>
<td></td>
<td>Economical limitations</td>
</tr>
<tr>
<td></td>
<td>Logistical problems</td>
</tr>
<tr>
<td></td>
<td>Immortality bias</td>
</tr>
</tbody>
</table>

Table 1 describes the main advantages and disadvantages of both RCTs and real life studies. Advantages and disadvantages of RCTs are associated to their strict design and population selection, which make their conclusion robust but distant from real life conditions. On the other side, real life studies reflect more closely related to usual care, but they provide results obtained in sub-optimal treatment conditions.
and characteristics of the study population, the randomization method, the control, the analysis method and all other phases or components of the trial [2].

The randomization process by which patients are allocated to treatment groups is a key element of RCT design. It guarantees that the groups are equal and comparable in all known and unknown characteristics that could potentially influence outcomes [2,12]. With this type of distribution, the groups differ only in their exposure to the treatment investigated [22]. This procedure avoids selection bias since every person has the same probability of receiving the test treatment(s) or the control [12].

In addition to randomization, also blinding reduces the possibility of bias. In a well-designed RCT, people directly involved in the study do not know how patients were allocated to treatments [23]. This avoids confounding factors linked to subjective perception of therapeutic effects because patients and health-care providers managing the therapy administration are unaware of the treatment assigned. Blinding of outcome assessors increases the reliability of the results because it assures the same interest and attention to each patient and to every result, minimizing also detection bias, i.e. systematic errors linked to evaluation of the results [23,24]. A distinctive feature of RCTs is the presence of a control for comparison. With proper controls, an RCT can provide a relative evaluation of efficacy, increasing the consistency of the conclusions. Controls for comparison allow a more objective evaluation of the effect and increase the robustness of the study design.

RCTs require an analytical approach to data analysis, to avoid methodical systematic bias. This is typically obtained by using ITT analysis [23,25], one of the strongest methods to prevent analytical bias [13,23].

ITT analysis considers that all patients belong to the groups to which they were initially randomly assigned, even if they subsequently withdraw or move/skip to another treatment group. Patients who do not receive the assigned treatment should not be excluded from the planned analysis since they usually do not have the same prognostic features as the others [23].

2.3. RCTs: limitations

Even the best RCT has limitations, because its well-defined structure implies some artifacts. Indeed, although RCTs are precious tools to assess treatment efficacy, their applicability is restricted to ideal conditions and this limits their ability to portray what happens in the real world [7,14,26–29] (Table 1).

One of the more relevant limitations of RCTs is a direct consequence of rigorous patient selection based on selective inclusion and exclusion criteria [7]. The reason behind such selective enrollment is to minimize the presence of confounding factors [7]. Thus, a “trial” population is selected and differs from the general population [30]. A Norwegian study recently evaluated the magnitude of this difference by assessing the actual population referred to an asthma clinic using the inclusion and exclusion criteria commonly adopted in RCTs in asthma (e.g. non-smokers with a defined range of airflow obstruction and no comorbidities, 1–2 exacerbation in the previous 12 months but none in the last month, symptomatic or not when treated with specified doses/types of medication). They found that less than 3% of the real population would be eligible for randomization. This is clearly not representative of the asthma population attending an asthma clinic in real life [31]. A similar study reported that less than 20% of patients with COPD meet the usual enrollment criteria for RCTs in COPD [31]. More recently, it has been confirmed that, by applying the commonly adopted inclusion/exclusion criteria to a large population of individuals with an established diagnosis of COPD, less than one out of five patients would be eligible for the RCTs [32]. Consequently, RCTs do not consider a number of factors that potentially influence outcomes in real life [14,33–37]. In particular, tobacco smoking, concomitant diseases, adherence to treatment should be considered because it affects responsiveness to corticosteroids [29,38,39], the first choice treatment for asthma.

Interestingly, the majority of asthma trials do not accept current/former smokers, while the majority of COPD trials exclude asthmatics, so there are no data on the large subgroup of patients (~30%) who have poor lung function and unfavorable clinical outcomes (e.g. frequent hospitalizations) [29,40–43]. Elderly asthmatic patients are another group traditionally excluded from RCTs, even though this clinically relevant population experiences high rates of hospitalization and asthma related death [29,44,45]. Excluding such patients and, for example those with comorbidities, results in a lack of treatment solutions in exactly the groups where they could have high clinical impact [29,46].

In clinical practice comorbidities are frequently encountered in patients with obstructive lung diseases. They are reported in more than 30% of asthmatic patients and in the majority (>60%) of COPD patients [31]. Concomitant diseases can affect the clinical manifestation of respiratory disorders (e.g. increasing risk of COPD exacerbations) [47,48] and their responsiveness to treatments (e.g. depression or other psychological problems reduce adherence to therapy, and obesity is associated to a lower response to inhaled corticosteroids) [49,50]. In addition, the presence of comorbidities can influence the pharmacological approach to obstructive lung diseases, e.g. the use of β2-agonists and of β blockers in patients with obstructive lung diseases and concomitant heart problems [48,51,52]. In general, the interplay between concomitant diseases/treatments cannot be properly assessed in RCTs.

On the other side, strict selection might focus only on patients who will respond better to the tested treatment leading to over-estimation of treatment effects [53]. Patients included in RCTs are usually adept at inhalation techniques: they are instructed on the use of inhalers and frequently monitored. Adherence to treatment is usually high in RCTs as this is a prerequisite for randomization, assessed during run-in: a sort of pre-selection of the population that can maximize treatment effects [14]. Clearly, this does not reflect everyday clinical practice, largely characterized by poor inhaler technique and low treatment observance [7,14,54]. In addition, subjects participating in RCTs are more likely to follow instructions [22,55]. Subjects enrolled in studies tend to pay closer attention to their health. This may minimizing any further advantages from the trial intervention and result in underestimation of preventive effects [22,55,56].

Interestingly, differences in patient selection criteria between RCTs may produce conflicting results for a given outcome [10,57]. For instance, there are contradictory data on the protective efficacy of bacillus Calmette–Guérin vaccine in the prevention of tuberculosis, probably linked to various diagnostic criteria used in different settings [10,58,59].

In addition to selection bias, RCTs have also a monitoring bias linked to the higher frequency of assessments and visits, compared to clinical practice [13]. The awareness of being monitored can influence outcomes by improving performance and reducing dissimilarities between different therapies. In addition, placebo effect may reduce the difference between active and control treatment, not only on subjective but also on objective measurements [14,60–62].

Another possible bias of RCTs derives from the clinical setting of the trial. Often the patient population is followed in specialized centers, where the available specialists and technologies differ from those in most general practice settings [11]. Thus, patient management in RCTs is not representative of usual care [11]. In addition, at variance with daily practice [63], RCTs usually comply with
international guidelines classifications to assess disease severity and treatment appropriateness.

RCTs have economical, logistical and ethical restrictions that can make them inappropriate for analyzing issues related to public health systems or unsuitable for specific conditions. For example, their design cannot be applied when evaluating rare conditions. Similarly, they cannot be utilized when the study concerns the cost, convenience, or safety of a therapy, but not its efficacy [2]. Moreover, RCTs do not take into account that each treatment becomes part of the complex health care system. This can potentially influence the use of the medication in daily practice in different ways, including accessibility and price/reimbursement, which often differ by country [2].

Because of feasibility limitations, RCTs usually assess a single distinct intervention in a specific setting. They have limited possibility to investigate the complex treatments common in real life, especially in the elderly and polymorbid populations [2,5]. For these reasons, the strict design of RCTs does not allow full detection of the side effects or complications associated with an intervention, particularly if these result from pharmacological interactions or concomitant comorbidities, or if they have a delayed onset [12,5,6]. Timing is another constraint with RCTs, which frequently have duration of weeks or few months [7,14,64]. Such a timeframe minimizes problems with management, costs, and patient withdrawals [764–66], but is significantly shorter than the usual treatment period for chronic respiratory diseases [13]. This limits their ability to provide reliable information on long-term treatment [2,14].

In summary, there is an urgent need for clinical information beyond that obtainable from classical RCTs. Recent concerns have been raised regarding the safety of the patients enrolled in RCT and exposed to a standard (not tailored) and unknown (double blinded) care [67]. Thus, it is not surprising that, in the past ten years, there has been an impressive increase in the number of the real life studies in asthma and COPD [68–75].

3. Real life studies

3.1. Real life studies: definition and features

Real life studies have been described in a variety of ways. The European Working Group on Relative Effectiveness has defined real life trials as a way to analyze medical data collected under real life conditions [27]. In essence, they are conducted in everyday settings, and for this reason, they provide insights into the real life effectiveness of a medical condition/intervention.

They can be observational or descriptive, i.e. non-interventional, or they can evaluate therapeutic interventions in usual care settings [27]. Numerous strategies have been described for collecting data to inform real world clinical decisions. Examples include databases, patient and population surveys, chart reviews, registries, observational studies and pragmatic clinical trials (Table 2) [27]. However, observational and pragmatic trials are the most widely used.

Observational studies are designed to monitor and describe real life management/treatment of clinical conditions, without interference from the strict rules that limit the generalizability of RCTs. They can be both prospective and retrospective and consist of cohort, case–control and cross-sectional studies [14]. By nature, they can assess large populations over long follow-up periods.

Pragmatic clinical trials are the type of real life studies closest to RCTs: they compare treatments/clinical interventions. At variance with RCTs, pragmatic trials are conducted in a routine care setting with heterogeneous patient populations and prolonged durations, which increase the likelihood of obtaining conclusions relevant to clinical practice [14,30,76–78].

The reliability and feasibility of analyzing data from real life sources are debated because of the variable quality of data from primary (medical records) or secondary (healthcare databases) sources [10,79]. For example, in different hospital databases the same pathological condition may be registered under different names (e.g. pulmonary fibrosis or interstitial lung disease) and this could influence subsequent data analysis. Whereas a single source usually registers such data under the same category; however, this means that any mistakes in diagnosis/management are repeated for all cases. Currently, there is no consensus on the best way to collect such data, but comparing the information obtained from various types of registries seems reasonable. When lung function data are available the risk of under/misdiagnosing obstructive lung diseases is reduced [80].

3.2. Real life studies: advantages

Real life studies reflect how treatments/interventions are administered in everyday clinical practice (Table 1). At variance to RCT, real life studies in asthma involve a heterogeneous non-selected population that includes smokers, all level of disease severity, atypical patients, patients with comorbidities, and those with low adherence and poor inhaler handling or inhalation technique [81,82]. This insures that every subject who potentially will receive the test treatment is represented in the study [81] Real life studies do not use inclusion and exclusion criteria: being non-selective they can include all the variables that can influence outcomes under real life conditions. This qualifying characteristic may lead to discrepancies with the results obtained by RCTs for a given outcome. Such is the case for asthma control, which is attained in a large proportion patients in RCTs, but not in real life conditions [7,83]. This may be due to differences in education on inhaler handling and in the choice of the most suitable inhaler for each patient [14,84]. RCTs and guidelines do not ascribe differences in clinical outcomes to inhalers [14,17,19,85–87], possibly because

<table>
<thead>
<tr>
<th>Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Types of real life studies.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Databases</td>
</tr>
<tr>
<td>Patient chart reviews</td>
</tr>
<tr>
<td>Observational data</td>
</tr>
</tbody>
</table>

This table describes the main types of real life studies, their features, including the source of data, and their applications in effectiveness studies.
patients in RCTs are adequately instructed in the proper use of their devices [14,88]. Conversely, differences emerge from real life studies, particularly in asthma, one of the first clinical conditions in which inhaler technique was investigated. An observational study revealed that using the same type of inhaler device for maintenance and rescue medication improved clinical results [89]. A cohort study demonstrated that monotherapy with inhaled corticosteroids (ICS) is more successful when patients use breath-actuated pressurized metered dose inhalers (BA-pMDIs) or dry powder inhalers (DPIs) rather than pressurized metered dose inhalers (pMDIs) [90]. Interestingly, the opposite was found for combination therapy ICS + long acting beta2 agonist (LABA), where a cohort study reported that a pMDI formulation of fluticasone—salmeterol provides greater benefits than a DPIs formulation [91]; moreover, a cross-sectional trial demonstrated that an extraneous formulation of beclomethasone—formoterol combination pMDI leads to better asthma control than ICS/LABA formulations DPIs [92]. These apparently conflicting results require careful interpretation but they underscore the importance of device selection and show how it can potentially influence clinical outcomes in real life.

Adherence to inhaled treatment is a major issue in routine practice and may represent another factor responsible for the difference between RCTs results from RCTs and real life studies. In a recent survey, 18% of patients with chronic respiratory disorders reported discontinuation of the prescribed inhaled treatment because of the difficulties in using the inhalers [93]. Several real life studies have assessed adherence to asthma medication with different formulations and treatment regimens. One study compared adherence rates to once-daily versus twice-daily mometasone furoate and found that the once-daily regimen is associated with better compliance [94]. Moreover, this study included non-adherent patients in the final analysis, thus providing valuable information for real life practice [94]. Evidence of how real life variables can subvert the ideal conclusions from RCTs was provided in a study on the efficacy of leukotriene receptor antagonists (LTRAs), a second line treatment for asthma in adults in RCT settings [95]. This study was a multicenter pragmatic trial that compared the real world effectiveness of 1) LTRA with low dose inhaled glucocorticoid as first-line asthma-controller therapy, and of 2) LTRA with LABA as add-on therapy in patients not controlled by low dose ICS [95]. The treatments were proven to be equivalent for asthma control, with a greater compliance to oral treatment compared to inhaled treatment, which contribute to make a second line oral treatment (LTRA) appear as effective as first choice inhaled treatment [95]. This was confirmed in children, where adherence to monotherapy with LTRA was better than to that of ICS [96]. Thus, in real life, higher adherence to an oral medication compared to an inhaled medication (ICS) may overturn the conclusions on efficacy obtained in RCTs [14,95,96].

Real life studies are immune to the logistical and ethical constraints that limit the feasibility of RCTs. The absence of these limitations endows observational studies with the power to assess outcomes such as hospitalization and mortality [16], and enables pragmatic trials to estimate cost-effectiveness under real life conditions [7,28]. Comparing the results from observational trials versus RCTs on these issues reveals that estimates of cost-effectiveness based on RCTs lack external validity [97], while real life studies are more reliable as they reflect everyday clinical practice [28].

The characteristics of real life studies make them useful tools for evaluating complex therapies, and policies for prescribing and management [7,6,98]. An observational study in patients experiencing an acute asthma attack reported on prescribing patterns before accessing the emergency department [99]. This analysis determined that a lack or delay in medical intervention substantially affected the level of optimal asthma management. Such information cannot be obtained from RCTs, where the disease management plan is pre-defined, including emergencies events, without variability in the treatment or timing of interventions [7,100]. In addition, at variance with RCTs, which usually compare treatments and placebo, real life studies are able to integrate alternative health care options, providing information on the management of complex interventions, which are very common in the routine healthcare setting and influence the clinical decision process [76]. A typical example is represented by the potential cardiovascular effects of bronchodilators in patients with cardiovascular comorbidities that are excluded from the majority of RCTs.

The nature and characteristics of real life studies make them the appropriate setting to assess safety. Their large scale and long duration in non-selected populations favor the identification of rare complications or interactions with other treatments.

An additional advantage of real life studies is their natural practice setting, e.g. physicians’ offices or clinics, which ensures that they have external validity [76]. Involvement of patients from different settings increases the variability of the results, but also reproduces the complexity of the health care system more reliably than the controlled conditions in RCTs [76].

Finally, real life studies have the benefit of longer durations than RCTs. This timing permits a more appropriate assessment of the long-term effects of medical interventions, and the identification of late side effects, by following the natural course of a disease [76].

Thus, real life studies have many positive features and play a key role in the investigation of clinical conditions and interventional opportunities. These intrinsic values explain the increasing importance of such studies in clinical research.

3.3. Real life studies: limitations

The limitations of real life studies are often intrinsically associated with their characteristic design (Table 1). The proximity to the real world, with all its complexity, including different disease manifestations, comorbidities, variable treatment adherence, suboptimal inhaler technique and multiple therapies, often dilutes the magnitude of a treatment effect [7].

The lack of patient selection, one of the most distinctive characteristics of real life studies, makes it impossible to avoid unmeasured confounding factors [11,29], while the absence of blinding and randomization does not always allow factors potentially influencing the outcomes to be properly balanced [14,53,101]. This is particularly true in studies with subjective outcomes, which can be influenced even by the patient’s awareness of the treatment they are assigned to [24,30]. However, this “knowledge effect” can be interpreted as a component of the treatment response that is normally present in clinical practice. Thus, it can be compared to a “placebo effect” and the difference between the overall treatment effect observed (including the knowledge effect) and the “placebo (knowledge) effect” can provide a reliable estimate of effectiveness [3].

Another challenge for real life studies is monitoring. Although real life studies are planned to avoid the strict monitoring of RCTs, some conditions, such as pragmatic trials, require frequent measurements and medical supervision [7,14,102–105]. This tight assessment can result in patient responses that differ from those attainable in routine clinical practice. Indeed, each extra visit potentially increases the patient’s response to therapy [106,107].

Under real-life conditions, in the absence of randomization, severity of the underlying disease influences treatment decisions [108]. This results in “confounding by indication”, meaning that the perception of a different prognosis leads the physician to preferentially prescribe one of the available treatments. As a result, prognostic factors are not equally distributed among the patients treated with different therapies and the comparison is affected by disease
severity [108], when patients treated with one medication are systematically different from the other groups in terms of illness stage [53]. In addition, it is common clinical practice to follow severe patients more closely [108,109]. This difference in monitoring influences the results of real life studies. Sometimes the disease process requires specific medical intervention, so the disease, not its severity, represents the “confounding by indication” factor. In this case, the severity/prognosis is considered a subtype of “confounding by indication” [110]. An interesting example of this type of bias comes from pediatric studies suggesting that the development of asthma in children <5 years old is associated with the use of antibiotics [111,112]. This association was identified when antibiotics are prescribed for lower respiratory tract infections (LRTI) [113,114]. In this case, the increased risk of asthma could be associated with LTRI, rather than antibiotics. Indeed, children with severe LTRI requiring antibiotics may be predisposed to developing asthma [115].

Economical and logistical demands pose an additional challenge for real life studies. Indeed, long-term studies involving large populations require considerable financial resources [76] and are logistically complex to manage. Long follow-up may represent a barrier to patient retention throughout the entire study period. Moreover, large populations are required to detect small treatment differences or infrequent clinically events (e.g. rare side effects) [30].

Finally, in observational studies, the choice to treat is not strictly regulated and can be made at any time during the disease history/evolution. The results of observational studies showing that prescription of ICS for COPD reduces the risk of subsequent hospitalization and mortality were said to be affected by an “immortality bias” [116]. In these studies, patients were considered to be “exposed” to ICS, if it was prescribed within 90 days after hospital discharge [116]. By definition, exposed patients could not incur rehospitalization or mortality (outcomes of the assessment) before glucocorticoids were prescribed [117]. Thus, they were technically outcome-free for up to 90 days, the so-called “immortal” follow-up time. This potentially leads to overestimation of the effect of ICS on these outcomes [16,117].

Therefore, it emerges that, although they reproduce real life conditions, real life studies sometimes differ from authentic routine clinical practice. Every artifact, large or small, potentially averts from genuine results.

3.4. Real life studies: overcoming some of the limitations

Investigators have acknowledged the limitations of real life studies and the search for solutions has begun (Table 3). A good starting point for increasing reliability is to establish a study plan with a critical design, a priori [7]. Given the importance of balancing the variables among the groups assessed, even observational cohorts can be designed with eligibility criteria. Enrolling patients with specific characteristics can improve the consistency of the results [118].

The study report should be prepared following strict guidelines that aim for the correct, accurate and reliable presentation of results [7,77,119]. For this purpose, the Consolidating Standards of Reporting Trials (CONSORT) statement, initially created for the standardization of RCTs [120], has been extended to cover also pragmatic cluster trials, where randomization applies to groups rather than to individuals [121,122]. The CONSORT guide is a checklist of items to incorporate in the study report in order to provide a clear explanation of study procedures and analyses. This guide also suggests that a flow diagram be used to specify the role and position of every subject involved in management of study [7,77].

Similarly, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement is a systematic checklist of items that define the characteristics of an observational study [119]. These tools for transparent reporting facilitate clear reporting of data and help editors, reviewers and readers to critically evaluate the aim and results of clinical studies [119].

Sources of bias linked to the timing of follow-up, such as the “immortal period”, can be addressed by using a time-dependent analysis that includes all treatments prescribed after enrollment, and arranging follow-up using a time-varying approach [16]. This more complete analysis permits a better understanding of temporal dynamics [16].

The absence of randomization clearly limits the reliability of conclusions from real life studies; however, differences between groups can be minimized. One of the most effective methods to control for equality between groups is propensity score matching [123]. This analysis quantifies the probability that a patient will receive treatment, assigning a numerical value based on disease severity, concomitant diseases, clinical history, prognostic parameters and other variables [124]. Subjects in different treatment groups are then matched 1:1 for the same propensity score value to neutralize imbalances between groups [102,125,126]. The analysis may use propensity scores in a variety of ways, for example for stratifying and matching treated and untreated patients [124,125,127–129]. Identifying the true confounding parameters that should be included in the model represents a challenge and is the object of debate [101]. Some relevant recommendations suggest that the propensity scores should be based on all variables potentially related to the outcome [129,130], or any variables linked with treatment choice and results [123]. This method helps to balance the occurrence of confounders between treated and untreated groups [101]. Propensity scores for studies on asthma should be based on all the determinants of asthma control and severity, the frequency of exacerbations and short acting beta2-agonist use [14,131].

Regarding COPD, the most recent study to use propensity score matching to counterbalance the absence of randomization and potential confounding factors was the PATHOS trial. This Swedish retrospective, observational study compared exacerbation rates (defined as hospitalizations, emergency visits and administration of physician visits) in patients with COPD receiving LTRI or ICS [113,114]. This study aimed to compare the results of real life studies with those of RCTs, focusing on the endpoints of time to first exacerbation, time to first hospitalization and time to first physician visit. The results showed that the use of ICS was associated with a significant reduction in the number of exacerbations, hospitalizations and physician visits, compared to LTRI [113,114].

Finally, in order to address the “immortality bias”, a time-dependent analysis was performed, adjusting for the duration of ICS exposure before the event of interest. The results showed a significant reduction in the number of exacerbations, hospitalizations and physician visits, compared to LTRI [113,114].

Table 3

<table>
<thead>
<tr>
<th>Problem or limitation</th>
<th>Solution purposes</th>
<th>Complementarities by RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lack of patient selection brings confounding factors</td>
<td>A priori strict critical design.</td>
<td>Rigorous experimental design</td>
</tr>
<tr>
<td>Lack of randomization</td>
<td></td>
<td>Randomization</td>
</tr>
<tr>
<td>Absence of blinding</td>
<td>Report the results in a correct, accurate and reliable way following appropriate statements.</td>
<td>Rigorous analytical method</td>
</tr>
<tr>
<td>Residual monitoring bias</td>
<td>Time-dependent analysis.</td>
<td>Rigorous experimental design</td>
</tr>
<tr>
<td>Immortality bias</td>
<td>Propensity score.</td>
<td>Rigorous analytical method</td>
</tr>
<tr>
<td>Confounding by indication</td>
<td></td>
<td>Randomization</td>
</tr>
</tbody>
</table>

Table 3 describes the main limitations of real life studies and the recent purposed solutions. It also underlines complementarity between real life studies and RCTs showing how some of these solutions derive from the analysis of RCTs strengths/advantages.
oral steroids or antibiotics for COPD) in patients with moderate to severe COPD who had been treated with either budesonide/formoterol or fluticasone/salmeterol [132]. Information was collected for more than 21,000 patients followed for up to 11 years from primary care medical records and data from national hospital, pharmacy and cause of death registries [132]. A propensity score was calculated based on age, gender, lung function, number of outpatient visits for acute exacerbations, number of prescriptions for other medications, significant comorbidities, and number of previous hospitalizations [132]. A score between 0 and 1 was given to each patient and a very tight matching was performed. Two matched cohorts of 2734 patients each were identified, with a follow-up comprising more than 19,000 patient-years. The study reports that treatment with budesonide/formoterol significantly reduces the number of exacerbations and hospitalizations compared to fluticasone/salmeterol [132].

4. Conclusions

RCTs are essential research tools with strong internal validity but low generalizability to real life conditions [7,14]. Thus, there is an increased interest in real life studies because of their close association with routine clinical practice [7]. Unfortunately, the main limitation of these latter studies is the lack of internal validity. RCTs and real life studies have opposite strengths, in terms of validity. This has both negative and positive implications. On the negative side, results obtained from only one type of study should be interpreted cautiously [82]. On a positive note, these approaches are complementary, so combining them increases their relative effectiveness and efficiency [59].


